Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Large Increase in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 7,780,000 shares, an increase of 94.5% from the December 15th total of 4,000,000 shares. Based on an average daily trading volume, of 100,730,000 shares, the short-interest ratio is currently 0.1 days. Approximately 4.2% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a report on Thursday, January 9th. They set a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Up 0.7 %

Shares of TNXP stock traded up $0.00 during trading hours on Thursday, hitting $0.23. 55,722,110 shares of the company were exchanged, compared to its average volume of 66,936,844. Tonix Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $12.48. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The business has a 50 day moving average of $0.26 and a two-hundred day moving average of $0.31. The company has a market capitalization of $43.73 million, a PE ratio of 0.00 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Analysts anticipate that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.